Form 4: Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer Sells $1.1 Million in Stock

Executive Vice President Andrew S. Boyer sold 125,000 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock on March 5, 2025, at an average price of $8.89 per share.

Summary

• Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals, Inc., reported a transaction involving the sale of Class A Common Stock.
• On March 5, 2025, Boyer sold 125,000 shares at a weighted average price of $8.89 per share.
• The total value of the shares sold is approximately $1.1 million.
• Following the transaction, Boyer directly owns 290,106 shares of Amneal Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting a stock sale. The sentiment depends on the investor's interpretation of the sale; it could be seen as slightly negative if investors believe the executive is losing confidence, or neutral if viewed as routine portfolio management.

Industry Context

Executive stock sales are a common occurrence and are often scrutinized by investors for insights into management's perspective on the company's future prospects. It's important to consider the size of the sale relative to the executive's total holdings and compare it to sales by other executives at Amneal and similar pharmaceutical companies.

Comparison to Industry Standards

• Executive stock sales are a common practice across the pharmaceutical industry.
• Comparing Boyer's transaction to similar sales by executives at companies like Teva, Mylan (now Viatris), or Endo can provide context.
• Analyzing the percentage of total holdings sold is crucial; a small percentage may be part of routine diversification, while a large percentage could raise concerns.

Stakeholder Impact

• The stock sale could potentially impact shareholder sentiment, depending on how the market interprets the transaction.

Key Dates